Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Central precocious puberty

Central precocious puberty

Part of Precocious Puberty

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Central precocious puberty

8 trials tracked for Central precocious puberty: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 62 citations.

8Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 5 Other / NA 1
  1. Phase 3 Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Completed · 62 cited
  2. Phase 3 Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty Completed · 35 cited
  3. Phase 4 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants Completed · 5 cited
  4. Phase 3 A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. Completed · 5 cited
  5. Phase 4 A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty Completed
  6. Phase 3 Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. Completed
Show 2 more trials
  1. Phase 3 Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Completed
  2. N/A A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Central precocious puberty: what the trials found

Leuprorelin Acetate Depot 3M has demonstrated high efficacy in managing central precocious puberty, with 97.47% of participants achieving peak LH suppression during GnRH stimulation at week 24 1. This intervention also showed a significant reduction in the ratio of bone age to chronological age (84.81%) and high rates of Tanner stage regression or non-progression by week 24 1.

Multiple GnRH agonists, including Triptorelin Pamoate and Histrelin, have shown consistent results in LH suppression. Triptorelin Pamoate achieved 100% LH suppression in multiple trials, with high rates of maintaining suppressed LH levels through month 12 [5, 6]. Additionally, Triptorelin demonstrated successful maintenance of LH suppression at prepubertal levels for up to 12 months 7.

Leuprolide Acetate and Leuprorelin have also shown established efficacy in this condition. Leuprorelin was associated with high rates of Tanner stage regression or non-progression at week 96 2. Leuprolide Acetate demonstrated LH suppression in approximately 50-54% of participants at 6 months, with corresponding bone age ratios ranging from 1.30 to 1.39 4.

Recent results — preliminary, needs further review

  • Enantone showed high rates of LH and FSH suppression below the upper limit value (98.1% to 100%) during the treatment phase, though results regarding Tanner stage regression were inconsistent across study arms 8.

For the clinician treating this condition

  • GnRH agonists such as Leuprorelin Acetate, Triptorelin, and Histrelin are established for achieving LH suppression and managing bone age progression in central precocious puberty.
  • Triptorelin Pamoate demonstrated 100% LH suppression rates and high consistency in maintaining prepubertal sex steroid levels 6.
  • Leuprorelin Acetate Depot 3M is associated with significant reduction in the ratio of bone age to chronological age at week 24 1.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GnRHa treatment for central precocious puberty is associated with 2.7 cm greater adult height gain
Diabetes & Endocrinology Meta-analysis
GnRHa treatment for central precocious puberty is associated with 2.7 cm greater adult height gain GnRHa treatment helps girls with early puberty gain height
This meta-analysis of 35 noncomparative and 21 comparative observational studies evaluates GnRHa treatment in children with Central Precocio…
Girls with central precocious puberty who receive GnRHa treatment may gain an average of 2.7 cm more in adult height compared to those witho…
Jul 16, 2026
Leuprolide acetate associated with final adult height exceeding mid-parental height in girls with central precocious puberty
Pediatrics Cohort
Leuprolide acetate associated with final adult height exceeding mid-parental height in girls with central precocious puberty More Than Half of Girls on Puberty Therapy Beat Their Genetic Height Potential
This retrospective cohort study included 73 girls with central precocious puberty or early puberty treated with depot leuprolide acetate.
More than half of girls treated for early puberty ended up taller than their genetic prediction, with younger age at treatment being the key…
Frontiers Apr 28, 2026
Quarterly triptorelin showed comparable hormonal suppression to monthly dosing in Chinese girls with central precocious puberty
Pediatrics Cohort
Quarterly triptorelin showed comparable hormonal suppression to monthly dosing in Chinese girls with central precocious puberty Less Frequent Injections Work Just as Well for Girls With Early Puberty
This retrospective cohort study evaluated 70 Chinese girls with central precocious puberty treated at Fuzhou First General Hospital.
Girls with early puberty treated with quarterly injections achieved the same growth protection as monthly shots in a new study.
Frontiers Apr 18, 2026
GnRHa treatment in familial hCG syndrome associated with concurrent beta-hCG elevation in blood and CSF
Diabetes & Endocrinology Sys. Review
GnRHa treatment in familial hCG syndrome associated with concurrent beta-hCG elevation in blood and CSF When a Pregnancy Hormone Shows Up in a Child — and It Is Not Cancer
This case report describes an 8-year-old girl with central precocious puberty treated with a gonadotropin-releasing hormone agonist (GnRHa).
An inherited condition can mimic a brain tumor in children by raising pregnancy hormones, leading to unnecessary surgery and chemotherapy be…
Frontiers Apr 14, 2026

Research across Precocious Puberty

Related studies from across the Precocious Puberty family.

Risk factors for intracranial lesions in males with central precocious puberty include neurological symptoms
Diabetes & Endocrinology Guideline
Risk factors for intracranial lesions in males with central precocious puberty include neurological symptoms New Research Identifies Genetic Links in Central Precocious Puberty
This clinical guideline reviews the etiology and risk factors of central precocious puberty (CPP) in males. It highlights a significant decr…
Recent data shows a significant drop in brain lesion prevalence among boys with precocious puberty compared to historical records.
Frontiers Jul 19, 2026
Meta-analysis links postnatal BPA exposure to increased odds of early pubertal onset in children
Pediatrics Meta-analysis
Meta-analysis links postnatal BPA exposure to increased odds of early pubertal onset in children Study finds link between BPA exposure and earlier puberty in girls
A systematic review and meta-analysis of 5,549 predominantly female children found higher postnatal BPA exposure was observationally associa…
Higher exposure to the plastic chemical BPA is linked to earlier puberty in girls, though this review cannot prove it causes the change.
Frontiers Apr 2, 2026

Questions about Central precocious puberty

Is there a link between central precocious puberty treatment and high beta-hCG levels in blood?

Treatment for central precocious puberty does not cause high beta-hCG levels; however, some rare genetic conditions can cause both central precocious puberty and high beta-hCG in the blood simultaneously.

Full answer →
Can leuprolide acetate help girls with central precocious puberty grow taller than their parents?

Research shows that girls with central precocious puberty treated with leuprolide acetate often reach a final adult height greater than their mid-parental height, meaning they can grow taller than their parents.

Full answer →